FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Marcus, Leigh; J. Lemery, Steven; Keegan, Patricia; Pazdur, Richard

doi:10.1158/1078-0432.ccr-18-4070

Public

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Published in Clinical Cancer Research • Feb 20, 2019

Authors:

Leigh Marcus

Steven J. Lemery

Patricia Keegan

Abstract

The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alt...

Subject

Pembrolizumab

Medicine

Irinotecan

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!